Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Txfor Renal Cancer

Telix doses first patient in Phase 3 renal cancer trial

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized, prospective, open label, multi-center study evaluating a CAIX-targeting radion…

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Txfor Renal Cancer

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Txfor Renal Cancer Melbourne (Australia) and Indianapolis, IN (United States) | July 21, 2026 First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). LUTEON is the first Phase 3 study of a CAIX[2]-targeted radiopharmaceutical therapy in ccRCC. Telix today announced that the first patient has been dosed wit…

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer